BUFIGEN is also used as an adjunct to standard or local anaesthesia and to provide pre and postoperative analgesia. It can be used during the 0.33 stage of exertion and diagnostic exam techniques that are potentially traumatic and painful. Pharmacokinetics: Nalbuphine is a potent opioid agonist-antagonist chemically related to naloxone and oxymorphone. It has the same analgesic potential as morphine, mg for mg. Analgesia appears to be produced by agonist actions in ky antagonistic actions at mu opioid receptors.
Mu receptors are widely distributed throughout the CNS, particularly in the limbic system, thalamus, striatum, hypothalamus, midbrain, and laminae I, II, IV, and V of the dorsal horn of the spinal wire. Because kappa receptors are concentrated in the spinal cord and cerebral cortex, these sites are involved in the areas where nalbuphine acts. Its movement begins about 2 minutes after being administered intravenously. When administered subcutaneously or intramuscularly, the effect starts within 15 minutes.
Analgesic motion lasts between three and six hours. Nalbuphine binds to plasma proteins approximately 30% of the time. It is metabolized in the liver and has a plasma half-life of 5 hours. It is mainly excreted in the feces with no current process changes and 7% in the urine as unchanged nalbuphine and conjugated metabolites.
Before taking any medication, consult your doctor. Dosage Form and Formulation Each vial of injectable solution contains the following ingredients: 10 mg nalbuphine hydrochloride Vehicle c.B.P. 1 ml Without the Republicans. Dosage and administration BUFIGEN Adults should take 10 mg per 70 kg body weight intravenously, intramuscularly, subcutaneously, or epidurally. As needed, the dose can be repeated every three to six hours. One hundred sixty mg is the maximum daily dose. The software allows for a maximum price of 20 mg. INDICATIONS: Analgesic. It is indicated to treat mild to severe pain, including acute myocardial infarction.